Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P210007/S015

Vivistim System

Mobia Medical, Inc. · Decision date Sep 16, 2026

MEDTECHLEDGER EXPLANATIONP210007/S015

What did the FDA decide?

The FDA recorded decision OK30 on 2026-09-16 for P210007/S015, a 30-Day Notice supplement to the Vivistim® System held by Mobia Medical, Inc. The supplement reason is listed as a process change involving manufacturer, sterilizer, packager or supplier. The device category is an implanted autonomic nerve stimulator for stroke rehabilitation, with product code QPY and Physical Medicine as the specialty.

The recorded change concerns one component: Mobia Medical replaced the supplier of the Lead Connector Boot used in the Implantable Lead of the Vivistim Paired VNS System, moving from Trelleborg to ProMed. This notice covers that supplier substitution, not a new approval of the full system. The source does not include supporting documents, review detail, or any clinical or performance findings, so the basis for OK30 and any effect on the finished lead remain unknown.

FDA approval order statement

Mobia Medical has replaced their supplier for the Lead Connector Boot component of the Implantable Lead of the Vivistim Paired VNS System, transitioning from Trelleborg to ProMed.
Regulatory pathway
PMA supplement
Supplement type
30-Day Notice
Clinical specialty
Physical Medicine
Decision date
Sep 16, 2026
FDA change category
Process Change - Manufacturer/Sterilizer/Packager/Supplier

FDA source record · MedtechLedger’s explanation describes the recorded change.

Regulatory record facts

Identifier
P210007/S015
Regulatory pathway
PMA supplement
Product code
QPY
Decision code
OK30
Decision date
Sep 16, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Stimulator, autonomic nerve, implanted for stroke rehabilitation.

Product code
QPY
FDA device class
3

For the original device and its historical approval scope, see PMA P210007. Subsequent supplements may change the device or its indications.

FDA decision timeline

  1. P210007/S015 received

    Application receipt date recorded by FDA.

  2. P210007/S015 · FDA decision

    30-Day Notice

Timeline entries are records held by MedtechLedger for P210007. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P210007

Product / regulatory recordCompanyPathwayDecision dateSource
Mobia Medical, Inc.PMA approvalAug 27, 2021FDA

Explore the linked device profile

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Mobia Medical, Inc.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
2802 Flintrock Trace, Suite 226, Austin, TX, 78738

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records